JZP 110

Drug Profile

JZP 110

Alternative Names: ADX-N05; ARL-N05; JZP-110; SKL-N05

Latest Information Update: 04 May 2017

Price : $50

At a glance

  • Originator SK Holdings
  • Developer Jazz Pharmaceuticals plc; SK biopharmaceuticals
  • Class Sleep disorder therapies
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Neurotransmitter modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Narcolepsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Narcolepsy; Sleep apnoea syndrome
  • Phase II Hypersomnia
  • No development reported Depressive disorders

Most Recent Events

  • 26 Apr 2017 Efficacy and adverse events data from the phase III TONES 2 trial in Narcolepsy syndrome released by Jazz Pharmaceuticals
  • 20 Mar 2017 Jazz pharmaceuticals announces intention to submit NDA to US FDA for Sleep apnoea syndrome and Narcolepsy in the Second half of 2017
  • 20 Mar 2017 Interim efficacy and adverse events data from the phase III TONES 3 and TONES 4 trials in Sleep apnoea syndrome released by Jazz Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top